The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Ibrutinib and FCR in CLL irrespective of IGHV mutation status
Whilst ibrutinib is effective in patients with chronic lymphocytic leukemia (CLL), fludarabine, cyclophosphamide, rituximab (FCR) is the only therapy effective in patients with mutated IGHV CLL. Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, presents data from the Phase II trial (NCT02251548) of ibrutinib plus FCR (iFCR) in patients with CLL regardless of IGHV status. The regimen resulted in high rates of undetectable minimal residual disease (MRD) irrespective of mutational status and after 40 months of follow-up, a majority of patients remain in deep remission. For a small number of patients who had myelodysplastic syndrome (MDS) as a result of iFCR, transplantation successfully reversed their condition. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Disclosures
Matthew Davids, MD, has received consultancy fees from AbbVie, BeiGene, Adaptive Biotechnologies, Janssen, Takeda, Merck, Eli Lilly and Company, and Celgene; consultancy fees and research funding from Pharmacyclics, Astra-Zeneca, BMS, TG Therapeutics, Genentech, MEI Pharma, Novartis, Verastem, Ascentage Pharma, and Surface Oncology.
